<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825002</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0305</org_study_id>
    <nct_id>NCT04825002</nct_id>
  </id_info>
  <brief_title>Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor</brief_title>
  <official_title>Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Medial Device Development Fund grant funded by the Korean government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to develop and validate the urinary multimarker sensor which can measure&#xD;
      trace amounts of biomarkers from naturally voided urine in men referred with clinical&#xD;
      suspicion of prostate cancer who have had no prior prostate biopsy. The investigators&#xD;
      hypothesize that urinary multimarker sensor will help to avoid unnecessary prostate biopsy&#xD;
      while detect the clinically significant cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will develop a urinary multimarker sensor, able to measure trace amounts of&#xD;
      biomarkers from naturally voided urine.&#xD;
&#xD;
        1. Urine specimen collection. This study was approved by the Institutional Review Board of&#xD;
           the Asan Medical Center (Seoul, Republic of Korea) and informed consent will be obtained&#xD;
           from all subjects. Biomarkers diffused passively from prostate tissue to the urethra and&#xD;
           will be collected from naturally voided urine. Urine will be collected in a sterilized&#xD;
           specimen cup containing 10 vol% RNA stabilizer and 1vol% antibiotics and stored in a&#xD;
           refrigerator for less than a week before shipping the sample to the laboratory&#xD;
&#xD;
        2. To measure the electrical signals from the four different biomarkers in the urine, the&#xD;
           four sensing channels in the extended gate of an field-effect transistor biosensor will&#xD;
           be conjugated to antibodies, thus capturing different biomarkers.&#xD;
&#xD;
        3. Without any pretreatment, urine will be added directly to the four different sensing&#xD;
           channels. After 20 min of reaction time in the four channels, the bottom gate voltage&#xD;
           shifts will be measured at the reference current (1 nA). Each urine sample will generate&#xD;
           four independent sensing signals from the corresponding biomarkers. The set of sensing&#xD;
           signals collected for each patient will be then analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence vs. absence of clinically significant prostate cancer on prostate biopsy</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>(≥Gleason score 3+4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence vs. absence of overall prostate cancer</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>presence or absence of prostate cancer at prostate biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal cutoff points for the each biomarker</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>cutoff points for each biomarker (ANXA3, PSMA, ERG, ENG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of each biomarker</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>sensitivity, specificity, positive/negative predictive value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (Receiver operating curve) by multivariable linear regression model</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Area Under Curve for each biomarker alone or combination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Urinary multimarker sensor arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urinary multimarker sensor</intervention_name>
    <description>We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.</description>
    <arm_group_label>Urinary multimarker sensor arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men undergoing a first-time prostate biopsy to rule out cancer&#xD;
&#xD;
          2. Serum PSA ≥3ng/mL, ≤20ng/mL&#xD;
&#xD;
          3. Age≥50 years, ≤80 years&#xD;
&#xD;
          4. Clinical stage ≤T2c&#xD;
&#xD;
          5. Patients must be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients has any prior needle biopsy of the prostate&#xD;
&#xD;
          2. Patients has a prior history of prostate cancer&#xD;
&#xD;
          3. Patients has a prior history of pelvic radiation therapy or androgen deprivation&#xD;
             therapy&#xD;
&#xD;
          4. Patients has a prior history of BPH operation&#xD;
&#xD;
          5. Patient with uncorrectable coagulopathies&#xD;
&#xD;
          6. Unable to tolerate a TRUS guided biopsy.&#xD;
&#xD;
          7. Patients had 5-alpha reductase inhibitor in the past six months.&#xD;
&#xD;
          8. The patient has had a urinary tract infection or acute prostatitis in the last three&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Choung-Soo Kim, MD</last_name>
    <phone>82-2-3010-3734</phone>
    <email>cskim@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Gab Jeong, MD</last_name>
      <phone>82-2-3010-5892</phone>
      <email>igjeong@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Bumjin Lim, MD</last_name>
      <phone>82-2-3010-1835</phone>
      <email>lbj1986@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>In Gab Jeong, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>In Gab Jeong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>biopsy</keyword>
  <keyword>urine</keyword>
  <keyword>biomarker</keyword>
  <keyword>nanoparticle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

